COMP <GO>
AORT vs PRCT // ENTERPRISE SCALE & MARKET CAP
Artivion Inc. (NYSE) VS. PROCEPT BioRobotics Corporation (NASDAQ) • 15-METRIC TALLY: AORT 6
— PRCT 4
▲ ENTERPRISE SCALE & MARKET CAP LEADER: PRCT
LAST: $23.44 (+2.27%) • MKT CAP: $1.14B
market-cap
$1.14B
LAST: $20.30 (+0.50%) • MKT CAP: $1.16B
market-cap
$1.16B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AORT VS. PRCT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AORT | PRCT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.40% | 63.70% | +0.70 | AORT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.50% | -35.00% | +39.50 | AORT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.07% | -5.02% | +5.09 | AORT | /fcf-yield <GO> |
| Operating Margin | 7.60% | -33.70% | +41.30 | AORT | /operating-margins <GO> |
| Net Profit Margin | 2.20% | 0.00% | +2.20 | AORT | /net-margins <GO> |
| Revenue Growth (YoY) | 13.60% | 37.20% | -23.60 | PRCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.46 | 3.98 | -1.52 | PRCT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 4/9 | +5.00 | AORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.6 | 50.7 | -4.14 | PRCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 98.3x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.14B | $1.16B | -$19.8M | PRCT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AORT REV | PRCT REV | AORT GROSS % | PRCT GROSS % | AORT FCF | PRCT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $441.3M | $308.1M | 64.4% | 63.7% | $839.0K | -$58.3M |
| FY 2024 | $388.5M | $224.5M | 64.0% | 61.1% | $11.0M | -$103.6M |
| FY 2023 | $354.0M | $136.2M | — | — | $18.8M | -$108.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AORT // BETA —
PRCT // BETA —